AstraZeneca PLC Financials - Benzinga

AstraZeneca PLC

AZNCFOTC

Trade with Public

Trade with Public

$187.10

3.932.15%

At close: Jan 29, 4:00 PM EST

Overview NewsFinancialsSentiment Compare

AstraZeneca PLC Financials

AstraZeneca PLC (AZNCF) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

AstraZeneca Q2 Earnings Beat Consensus Despite Zero COVID-19 Vaccine Sales, Stock Shoots Up

AstraZeneca Plc's (NASDAQ: AZN) unit Alexion has

Vandana Singh

AstraZeneca's COVID-19 Vaccine Loses Shine, Cancer Drug Imfinzi & Emerging Markets Stabilize Q1 Revenues

AstraZeneca Plc (NASDAQ: AZN) has reported Q1 FY23 core EPS of $1.92, up 1% Y/Y (+6% on constant currency), better than the consensus of $1.07. The company clocked Q1 sales of $10.88 billion, -4% (flat CC), beating the consensus of $10.75 billion.

Vandana Singh

Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively

Vandana Singh

AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade

Vandana Singh

AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength

Vandana Singh

PRO
AstraZeneca Raises FY 2022 Adjusted EPS Growth To "High Twenties To Low Thirties Percentage." Previously, Expected "Mid-To-High Twenties Percentage."

Benzinga Newsdesk